114 related articles for article (PubMed ID: 34224182)
1. Clinical usefulness of noninvasive fibrosis indices for predicting hepatocellular carcinoma in treatment-naïve patients with chronic hepatitis B following entecavir therapy.
Jeong J; Shin JW; Jung SW; Lee SB; Park EJ; Park NH
Hepatol Res; 2021 Sep; 51(9):923-932. PubMed ID: 34224182
[TBL] [Abstract][Full Text] [Related]
2. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.
Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
J Gastroenterol Hepatol; 2019 Feb; 34(2):442-449. PubMed ID: 29968933
[TBL] [Abstract][Full Text] [Related]
3. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
[TBL] [Abstract][Full Text] [Related]
4. Comparison of FIB-4 index and aspartate aminotransferase to platelet ratio index on carcinogenesis in chronic hepatitis B treated with entecavir.
Nishikawa H; Nishijima N; Enomoto H; Sakamoto A; Nasu A; Komekado H; Nishimura T; Kita R; Kimura T; Iijima H; Nishiguchi S; Osaki Y
J Cancer; 2017; 8(2):152-161. PubMed ID: 28243319
[TBL] [Abstract][Full Text] [Related]
5. Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis.
Shin SK; Yim HJ; Kim JH; Lee CU; Yeon JE; Suh SJ; Jung YK; Kim YS; Kim JH; Kwon OS
Gut Liver; 2021 May; 15(3):430-439. PubMed ID: 33115966
[TBL] [Abstract][Full Text] [Related]
6. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir.
Chiang HH; Lee CM; Hu TH; Hung CH; Wang JH; Lu SN; Lai HC; Su WP; Lin CH; Peng CY; Chen CH
Liver Int; 2018 Nov; 38(11):1997-2005. PubMed ID: 29797410
[TBL] [Abstract][Full Text] [Related]
7. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients.
Sou FM; Hu TH; Hung CH; Lai HC; Wang JH; Lu SN; Peng CY; Chen CH
Hepatol Int; 2020 Jul; 14(4):513-520. PubMed ID: 32319045
[TBL] [Abstract][Full Text] [Related]
8. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive Tests for Fibrosis Predict 5-Year Mortality and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
Kim JH; Kim JW; Seo JW; Choe WH; Kwon SY
J Clin Gastroenterol; 2016; 50(10):882-888. PubMed ID: 27322532
[TBL] [Abstract][Full Text] [Related]
10. On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma.
Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32392752
[TBL] [Abstract][Full Text] [Related]
11. Predictive score for hepatocellular carcinoma after hepatitis B e antigen loss in patients treated with entecavir or tenofovir.
Lim TS; Lee HW; Lee JI; Kim IH; Lee CH; Jang BK; Chung WJ; Yim HJ; Suh SJ; Seo YS; Lee HA; Yu JH; Lee JW; Kim SG; Kim YS; Park SY; Tak WY; Kim SS; Cheong JY; Jeong SW; Jang JY; Rou WS; Lee BS; Kim SU;
J Viral Hepat; 2020 Oct; 27(10):1052-1060. PubMed ID: 32383246
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic accuracy of APRI and FIB-4 for predicting hepatitis B virus-related liver fibrosis accompanied with hepatocellular carcinoma.
Xiao G; Zhu F; Wang M; Zhang H; Ye D; Yang J; Jiang L; Liu C; Yan L; Qin R
Dig Liver Dis; 2016 Oct; 48(10):1220-6. PubMed ID: 27599803
[TBL] [Abstract][Full Text] [Related]
13. The FIB-4 index is a significant prognostic factor in patients with non-B non-C hepatocellular carcinoma after curative surgery.
Okamura Y; Ashida R; Yamamoto Y; Ito T; Sugiura T; Bekku E; Aramaki T; Uesaka K
Langenbecks Arch Surg; 2016 Mar; 401(2):195-203. PubMed ID: 26943655
[TBL] [Abstract][Full Text] [Related]
14. Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients.
Mak LY; Ko M; To E; Wong DK; Ma JH; Hui TL; Seto WK; Fung J; Lai CL; Yuen MF
J Gastroenterol Hepatol; 2019 Oct; 34(10):1817-1823. PubMed ID: 30786068
[TBL] [Abstract][Full Text] [Related]
15. Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia.
Paik N; Sinn DH; Lee JH; Oh IS; Kim JH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Liver Int; 2018 Jan; 38(1):68-75. PubMed ID: 28581248
[TBL] [Abstract][Full Text] [Related]
16. Changes of FibroScan, APRI, and FIB-4 in chronic hepatitis B patients with significant liver histological changes receiving 3-year entecavir therapy.
Li Q; Chen L; Zhou Y
Clin Exp Med; 2018 May; 18(2):273-282. PubMed ID: 29350286
[TBL] [Abstract][Full Text] [Related]
17. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
[TBL] [Abstract][Full Text] [Related]
18. Fibrosis-4 index, a predictor for prognosis of hepatocellular carcinoma patients after curative hepatectomy even in hepatitis B virus dominant populations.
Yun SO; Kim JM; Rhu J; Choi GS; Joh JW
Ann Surg Treat Res; 2023 Apr; 104(4):195-204. PubMed ID: 37051160
[TBL] [Abstract][Full Text] [Related]
19. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of the Fibrosis-4 index and alanine aminotransferase at 1 year of nucleos(t)ide analog treatment for prediction of hepatocellular carcinoma in chronic hepatitis B patients.
Inoue J; Akahane T; Kobayashi T; Kimura O; Sato K; Ninomiya M; Iwata T; Takai S; Kisara N; Sato T; Nagasaki F; Miura M; Nakamura T; Umetsu T; Sano A; Tsuruoka M; Onuki M; Sawahashi S; Niitsuma H; Masamune A;
Hepatol Res; 2024 Feb; 54(2):131-141. PubMed ID: 37621201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
